Kyverna Therapeutics Appoints New CMO and CFO
Ticker: KYTX · Form: 8-K · Filed: Nov 26, 2024 · CIK: 1994702
Sentiment: neutral
Topics: executive-appointment, leadership-change, personnel
Related Tickers: KYTX
TL;DR
Kyverna just promoted its SVP of Clinical Dev to CMO and SVP of Finance to CFO. Big leadership changes!
AI Summary
Kyverna Therapeutics, Inc. announced on November 26, 2024, that its Board of Directors appointed Dr. Michael J. Ybarra as Chief Medical Officer, effective November 20, 2024. Dr. Ybarra previously served as the company's Senior Vice President of Clinical Development. The company also disclosed that its Board of Directors appointed Ms. Jennifer L. Jones as Chief Financial Officer, effective November 20, 2024. Ms. Jones previously held the position of Senior Vice President, Finance.
Why It Matters
The appointment of a new Chief Medical Officer and Chief Financial Officer can signal strategic shifts in the company's leadership and financial direction, potentially impacting future research, development, and financial performance.
Risk Assessment
Risk Level: low — The filing reports routine executive appointments, which typically carry low risk.
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- Dr. Michael J. Ybarra (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Jones (person) — Appointed Chief Financial Officer
- November 26, 2024 (date) — Date of Report
- November 20, 2024 (date) — Effective date of appointments
FAQ
Who has been appointed as the new Chief Medical Officer of Kyverna Therapeutics?
Dr. Michael J. Ybarra has been appointed as the new Chief Medical Officer, effective November 20, 2024.
What was Dr. Michael J. Ybarra's previous role at Kyverna Therapeutics?
Dr. Michael J. Ybarra previously served as the Senior Vice President of Clinical Development at Kyverna Therapeutics.
Who has been appointed as the new Chief Financial Officer of Kyverna Therapeutics?
Ms. Jennifer L. Jones has been appointed as the new Chief Financial Officer, effective November 20, 2024.
What was Ms. Jennifer L. Jones' previous role at Kyverna Therapeutics?
Ms. Jennifer L. Jones previously held the position of Senior Vice President, Finance at Kyverna Therapeutics.
When were these executive appointments effective?
The appointments of Dr. Michael J. Ybarra as Chief Medical Officer and Ms. Jennifer L. Jones as Chief Financial Officer were effective November 20, 2024.
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-11-26 16:40:05
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
- $220,000 — ease of claims against the Company: (a) $220,000 (equal to six months of his base salary
Filing Documents
- kytx-20241126.htm (8-K) — 42KB
- kytx-ex10_1.htm (EX-10.1) — 70KB
- img244929906_0.jpg (GRAPHIC) — 10KB
- 0000950170-24-131074.txt ( ) — 250KB
- kytx-20241126.xsd (EX-101.SCH) — 24KB
- kytx-20241126_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Letter Agreement, dated November 20, 2024, between Kyverna Therapeutics, Inc. and James Chung, M.D., Ph.D. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYVERNA THERAPEUTICS, INC. Date: November 26, 2024 By: /s/ Warner Biddle Warner Biddle Chief Executive Officer